{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/diagnosis/signs-symptoms/","result":{"pageContext":{"chapter":{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms","depth":2,"htmlHeader":"<!-- begin field 411ec6ad-830c-4bc0-9a97-a99d00fb8b23 --><h2>What are the signs and symptoms of acute pyelonephritis?</h2><!-- end field 411ec6ad-830c-4bc0-9a97-a99d00fb8b23 -->","summary":"","htmlStringContent":"<!-- begin item 75b4e130-7878-4a2c-b640-a99d00fb8ad0 --><!-- begin field 0c99f3bc-328e-4c3d-8bdc-a99d00fb8b23 --><ul><li>There are no clinical features or routine investigations that conclusively distinguish acute pyelonephritis from lower urinary tract infection.<ul><li>However, the triad of flank pain (typically unilateral), fever, and nausea and vomiting occurs much more often in people with pyelonephritis than in those with lower urinary tract infection.</li></ul></li><li>Onset is typically sudden with signs and symptoms of both systemic inflammation and bladder inflammation. </li><li><strong>Signs and symptoms of pyelonephritis include:</strong><ul><li>Kidney pain/tenderness in back under ribs.<ul><li>Flank pain, or costovertebral angle tenderness is present in 86% of people with pyelonephritis. </li></ul></li><li>New/different myalgia, flu-like illness.</li><li>Shaking chills (rigors) or temperature 37.9°C or above (or below 36°C in people aged over 65 years).<ul><li>Fever is found in 77% of people with pyelonephritis. </li><li>Fever may be absent in people with early or mild cases, frail, older people, or in the immunocompromised. </li></ul></li><li>Nausea/vomiting. </li></ul></li></ul><!-- end field 0c99f3bc-328e-4c3d-8bdc-a99d00fb8b23 --><!-- end item 75b4e130-7878-4a2c-b640-a99d00fb8ad0 -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"2e3de550-e8b3-5954-aa2c-d9b903a57c9c","slug":"basis-for-recommendation-695","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 4615b35a-b2a6-47cd-a969-a99e00f8d63a --><h3>Basis for recommendation</h3><!-- end field 4615b35a-b2a6-47cd-a969-a99e00f8d63a -->","summary":null,"htmlStringContent":"<!-- begin item 695b3b23-9b62-4969-8693-a99e00f8d60d --><!-- begin field b5fcfcf8-e229-4668-995e-a99e00f8d63a --><p>These recommendations are based on the Public Health England (PHE) guide <em>Diagnosis of urinary tract infections: quick reference tool for primary car</em>e [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">PHE, 2018</a>], the British Medical Journal (BMJ) best practice guide <em>Acute pyelonephritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BMJ, 2018</a>], and expert opinion in narrative reviews <em>Diagnosis and Treatment of Acute Pyelonephritis in Women</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Colgan, 2011</a>], and <em>Acute pyelonephritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Johnson, 2018</a>]. </p><!-- end field b5fcfcf8-e229-4668-995e-a99e00f8d63a --><!-- end item 695b3b23-9b62-4969-8693-a99e00f8d60d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}